Analysis of European policy towards generic medicines
Journal Title: Generics and Biosimilars Initiative Journal - Year 2014, Vol 3, Issue 1
Abstract
In this paper, we provide an overview of a PhD project we undertook on European policy on generic medicines. In the course of our research, we identified various causes for delayed market access of generic medicines and the need for policies to accelerate market access. These should work in conjunction with policies designed to influence demand, as these can significantly affect use of generic medicines. Ideally, demand-side policies should focus on promoting the use of generic medicines to physicians, pharmacists and patients, with or without financial incentives. Lastly, we present our recommendations for increasing the use of generic medicines.
Authors and Affiliations
Pieter Dylst, Arnold G Vulto, Steven Simoens
Keywords
Related Articles
- EP ID EP354229
- DOI 10.5639/gabij.2014.0301.011
- Views 122
- Downloads 0
Editor’s introduction to the wide range of topics in the initial issue of the second volume of GaBI Journal
We start off the second year of GaBI Journal with articles covering a wide range of issues.
Reference price systems: stakeholder dialogue and involvement
Dylst et al. provide a detailed overview about the characteristics of reference price systems in Europe and discuss their possible impact. The role of stakeholders in the implementation of this policy measure requires fu...
Critical immunogenicity differences will be obscured by a common INN for biosimilars
Information about variable immunogenicity arising from formulation differences between competing biosimilars is critical for informed judgments by prescribing physicians. Use of a common INN for biosimilars will obfuscat...
Do low- to middle-income countries need a biosimilar approval pathway based on a full comparability exercise?
Despite the fact that hepatitis C is a disease of global importance, many countries cannot afford the costly but effective combination treatment of peg-interferon and ribavirin, which was recently included in the World H...
Health professionals in the risk communication process on counterfeit medicines
Communication is a key component in the fight against counterfeit medicines affecting the lives of patients. Two types of risk communication should be distinguished: pro-active and reactive. Reactive communication can be...